NeuroPace Inc (NPCE) stock

NPCENasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/3013% above fair value

$7.56−4.46 (-37.10%)

Close on Nov 13, 2026Market cap $259.49MP/E –Yield 0.00%

NeuroPace r&d expenses

Research and development expenses are spending on new products and technology.

NeuroPace's R&D Expenses for the twelve months ending Sep 30, 2026 was $27.28M, up 1.4% year over year. For fiscal 2025 it was $27.89M, up 17.9% from the year before. The highest annual figure on record is $27.89M in fiscal 2025.

Annual r&d expenses

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$27.89M	+17.9%
FY2024	Dec 31, 2024	$23.65M	+13.8%
FY2023	Dec 31, 2023	$20.78M	-5.3%
FY2022	Dec 31, 2022	$21.95M	+20.5%
FY2021	Dec 31, 2021	$18.21M	+16.0%
FY2020	Dec 31, 2020	$15.70M	–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$6.17M	-6.2%
Q2 FY2026	Jun 30, 2026	$6.90M	+0.8%
Q1 FY2026	Mar 31, 2026	$7.19M	-3.4%
Q4 FY2025	Dec 31, 2025	$7.03M	+16.1%
Q3 FY2025	Sep 30, 2025	$6.58M	+14.3%
Q2 FY2025	Jun 30, 2025	$6.85M	+12.9%
Q1 FY2025	Mar 31, 2025	$7.44M	+28.6%
Q4 FY2024	Dec 31, 2024	$6.05M	+12.5%
Q3 FY2024	Sep 30, 2024	$5.75M	+20.0%
Q2 FY2024	Jun 30, 2024	$6.07M	+13.5%
Q1 FY2024	Mar 31, 2024	$5.78M	+9.9%
Q4 FY2023	Dec 31, 2023	$5.38M	+5.7%
Q3 FY2023	Sep 30, 2023	$4.80M	-14.5%
Q2 FY2023	Jun 30, 2023	$5.34M	-5.8%
Q1 FY2023	Mar 31, 2023	$5.26M	-5.6%
Q4 FY2022	Dec 31, 2022	$5.09M	-4.8%
Q3 FY2022	Sep 30, 2022	$5.61M	+29.6%
Q2 FY2022	Jun 30, 2022	$5.67M	+27.8%
Q1 FY2022	Mar 31, 2022	$5.58M	+36.0%
Q4 FY2021	Dec 31, 2021	$5.35M	+36.4%
Q3 FY2021	Sep 30, 2021	$4.33M	+17.3%
Q2 FY2021	Jun 30, 2021	$4.44M	+36.4%
Q1 FY2021	Mar 31, 2021	$4.10M	-15.2%
Q4 FY2020	Dec 31, 2020	$3.92M	–
Q3 FY2020	Sep 30, 2020	$3.69M	–
Q2 FY2020	Jun 30, 2020	$3.25M	–
Q1 FY2020	Mar 31, 2020	$4.83M	–